



## Vyxeos® (daunorubicin and cytarabine) – Expanded indication

- On March 30, 2021, [Jazz Pharmaceuticals announced the FDA approval of Vyxeos \(daunorubicin and cytarabine\)](#), for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
  - Vyxeos was previously approved for these indications in adults only.
- The approval of Vyxeos for the expanded indication was based on two single-arm trials evaluating the pharmacokinetics and safety of Vyxeos in children and young adults. Study AAML1421 evaluated 38 patients aged 1 to 21 years with AML in first relapse and study CPX-MA-1201 evaluated 27 patients aged 1 to 19 years with relapsed/refractory hematologic malignancies. Both studies did not find any differences in the safety profile by age. The efficacy of Vyxeos for patients aged 1 year and older was extrapolated from the [pivotal trial](#) in adults.
- Vyxeos has a boxed warning stating it should not be interchanged with other daunorubicin- and/or cytarabine-containing products.
- The recommended dosage of Vyxeos in pediatric patients is identical to current dosing recommendations for adults.
- Refer to the Vyxeos drug label for complete dosing and administration recommendations



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.